1. Home
  2. NEPH vs PRLD Comparison

NEPH vs PRLD Comparison

Compare NEPH & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEPH
  • PRLD
  • Stock Information
  • Founded
  • NEPH 1997
  • PRLD 2016
  • Country
  • NEPH United States
  • PRLD United States
  • Employees
  • NEPH N/A
  • PRLD N/A
  • Industry
  • NEPH Medical/Dental Instruments
  • PRLD Medicinal Chemicals and Botanical Products
  • Sector
  • NEPH Health Care
  • PRLD Health Care
  • Exchange
  • NEPH Nasdaq
  • PRLD Nasdaq
  • Market Cap
  • NEPH 42.6M
  • PRLD 44.0M
  • IPO Year
  • NEPH 2004
  • PRLD 2020
  • Fundamental
  • Price
  • NEPH $3.93
  • PRLD $1.25
  • Analyst Decision
  • NEPH Strong Buy
  • PRLD Strong Buy
  • Analyst Count
  • NEPH 2
  • PRLD 3
  • Target Price
  • NEPH $5.50
  • PRLD $4.00
  • AVG Volume (30 Days)
  • NEPH 50.3K
  • PRLD 219.0K
  • Earning Date
  • NEPH 11-06-2025
  • PRLD 11-05-2025
  • Dividend Yield
  • NEPH N/A
  • PRLD N/A
  • EPS Growth
  • NEPH N/A
  • PRLD N/A
  • EPS
  • NEPH 0.12
  • PRLD N/A
  • Revenue
  • NEPH $16,684,000.00
  • PRLD $7,000,000.00
  • Revenue This Year
  • NEPH $24.38
  • PRLD N/A
  • Revenue Next Year
  • NEPH $5.60
  • PRLD N/A
  • P/E Ratio
  • NEPH $32.97
  • PRLD N/A
  • Revenue Growth
  • NEPH 21.16
  • PRLD N/A
  • 52 Week Low
  • NEPH $1.36
  • PRLD $0.61
  • 52 Week High
  • NEPH $5.00
  • PRLD $5.53
  • Technical
  • Relative Strength Index (RSI)
  • NEPH 50.10
  • PRLD 60.92
  • Support Level
  • NEPH $3.62
  • PRLD $1.10
  • Resistance Level
  • NEPH $4.55
  • PRLD $1.26
  • Average True Range (ATR)
  • NEPH 0.35
  • PRLD 0.15
  • MACD
  • NEPH -0.04
  • PRLD 0.00
  • Stochastic Oscillator
  • NEPH 33.33
  • PRLD 81.13

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: